CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 162 filers reported holding CLOVIS ONCOLOGY INC in Q4 2019. The put-call ratio across all filers is 1.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $31,000 | -75.4% | 15,000 | -67.7% | 0.00% | – |
Q4 2021 | $126,000 | -45.2% | 46,431 | -10.1% | 0.00% | – |
Q3 2021 | $230,000 | +91.7% | 51,619 | +148.2% | 0.00% | – |
Q2 2021 | $120,000 | -60.9% | 20,800 | -52.5% | 0.00% | -100.0% |
Q1 2021 | $307,000 | +33.5% | 43,807 | -8.5% | 0.00% | – |
Q4 2020 | $230,000 | -19.3% | 47,864 | -2.0% | 0.00% | -100.0% |
Q3 2020 | $285,000 | +7.5% | 48,861 | +24.6% | 0.00% | 0.0% |
Q2 2020 | $265,000 | +13.2% | 39,200 | +6.2% | 0.00% | 0.0% |
Q1 2020 | $234,000 | -85.6% | 36,900 | -76.4% | 0.00% | -80.0% |
Q4 2019 | $1,627,000 | +106.2% | 156,036 | -22.3% | 0.01% | +66.7% |
Q3 2019 | $789,000 | -68.3% | 200,946 | +19.9% | 0.01% | -71.4% |
Q2 2019 | $2,491,000 | +819.2% | 167,555 | +1432.6% | 0.02% | +950.0% |
Q1 2019 | $271,000 | +59.4% | 10,933 | +88.5% | 0.00% | +100.0% |
Q3 2018 | $170,000 | -93.5% | 5,800 | -89.8% | 0.00% | -92.9% |
Q2 2018 | $2,596,000 | +5423.4% | 57,100 | +11140.2% | 0.01% | – |
Q3 2015 | $47,000 | – | 508 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 407,416 | $14,259,560,000 | 8.34% |
Palo Alto Investors LP | 3,547,719 | $124,170,000 | 6.91% |
Antipodean Advisors LLC | 1,268,658 | $44,403,000 | 6.48% |
Redmile Group, LLC | 1,795,936 | $62,858,000 | 4.70% |
HealthCor Management, L.P. | 1,525,000 | $53,375,000 | 3.24% |
PointState Capital LP | 3,503,900 | $122,637,000 | 3.12% |
NEA Management Company, LLC | 1,139,890 | $39,896,000 | 2.54% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 612,500 | $21,438,000 | 2.44% |
PFM Health Sciences, LP | 2,078,440 | $72,745,000 | 2.21% |
Partner Investment Management, L.P. | 35,300 | $1,236,000 | 2.03% |